Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL) - PubMed (original) (raw)
. 1993 Sep 9;55(2):237-44.
doi: 10.1002/ijc.2910550212.
Affiliations
- PMID: 7690346
- DOI: 10.1002/ijc.2910550212
Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL)
T Wölfel et al. Int J Cancer. 1993.
Abstract
We have pursued our analysis of potential tumor-rejection antigens recognized on human melanoma by autologous cytolytic T lymphocytes (CTL). We reported previously that 3 distinct antigens (A,B,C) were recognized on melanoma cell line SK29-MEL in association with HLA-A2. Selection for melanoma-cell variants resistant to anti-A CTL revealed that antigen A consists of at least 2 determinants (Aa, Ab) which can be lost separately. Genetic linkage between Aa and Ab was suggested by concomitant loss of Aa and Ab in an immunoselected tumor-cell variant. This variant was also resistant to an autologous CTL clone restricted by HLA-B45, indicating that this CTL may also recognize a determinant of antigen A. Of 11 allogeneic HLA-A2 melanoma cell lines that were tested, 5 expressed both Aa and Ab, 1 expressed only Aa, and 1 only Ab. None of them was lysed by anti-B or anti-C CTL clones. A CTL clone derived from another HLA-A2-melanoma patient was found to have exactly the same lytic pattern as the anti-Ab CTL of the first patient. This suggested that it may be possible to elicit an anti-Ab response in many HLA-A2 patients. We conclude that there are at least 2 distinct antigens presented in association with HLA-A2 that are common to many melanomas and therefore constitute promising targets for specific immunotherapy.
Similar articles
- Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde KH, Wölfel T. Schneider J, et al. Int J Cancer. 1998 Jan 30;75(3):451-8. doi: 10.1002/(sici)1097-0215(19980130)75:3<451::aid-ijc20>3.0.co;2-a. Int J Cancer. 1998. PMID: 9455808 - Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H, Jäger E, Maeurer MJ, Meyer zum Büschenfelde KH, Knuth A. Bernhard H, et al. Tissue Antigens. 1996 Jul;48(1):22-31. doi: 10.1111/j.1399-0039.1996.tb02601.x. Tissue Antigens. 1996. PMID: 8864171 - Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.
Wölfel T, Klehmann E, Müller C, Schütt KH, Meyer zum Büschenfelde KH, Knuth A. Wölfel T, et al. J Exp Med. 1989 Sep 1;170(3):797-810. doi: 10.1084/jem.170.3.797. J Exp Med. 1989. PMID: 2788708 Free PMC article. - Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.
Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T. Coulie PG, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. doi: 10.1097/00002371-199308000-00004. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280701 Review. - Attempts to optimize active specific immunotherapy for melanoma.
Mitchell MS. Mitchell MS. Int Rev Immunol. 1991;7(4):331-47. doi: 10.3109/08830189109114878. Int Rev Immunol. 1991. PMID: 1779176 Review.
Cited by
- Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis.
VanValkenburg A, Kaipilyawar V, Sarkar S, Lakshminarayanan S, Cintron C, Prakash Babu S, Knudsen S, Joseph NM, Horsburgh CR, Sinha P, Ellner JJ, Narasimhan PB, Johnson WE, Hochberg NS, Salgame P. VanValkenburg A, et al. Front Immunol. 2022 Sep 28;13:1011166. doi: 10.3389/fimmu.2022.1011166. eCollection 2022. Front Immunol. 2022. PMID: 36248906 Free PMC article. - Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
Goepfert K, Dinsart C, Rommelaere J, Foerster F, Moehler M. Goepfert K, et al. Front Oncol. 2019 May 28;9:425. doi: 10.3389/fonc.2019.00425. eCollection 2019. Front Oncol. 2019. PMID: 31192129 Free PMC article. - Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency.
Yoshida M, Ishioka Y, Ozawa T, Okuyama H, Iguchi M, Ota T, Ito T, Nagira M, Morita A, Tanaka H, Naito H, Kidoya H, Takakura N. Yoshida M, et al. Sci Rep. 2017 Sep 11;7(1):11137. doi: 10.1038/s41598-017-11605-2. Sci Rep. 2017. PMID: 28894200 Free PMC article. - Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.
Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M. Heinrich B, et al. Onco Targets Ther. 2017 May 2;10:2389-2401. doi: 10.2147/OTT.S126320. eCollection 2017. Onco Targets Ther. 2017. PMID: 28496337 Free PMC article. - Expanding the targets available to therapeutic antibodies via novel disease-specific markers.
Weidanz JA, Hildebrand WH. Weidanz JA, et al. Int Rev Immunol. 2011 Oct-Dec;30(5-6):312-27. doi: 10.3109/08830185.2011.608136. Int Rev Immunol. 2011. PMID: 22053971 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials